Share on StockTwits

Minerva Neurosciences (NASDAQ:NERV) Director Michele Ollier bought 1,620,833 shares of the company’s stock in a transaction that occurred on Monday, July 7th. The shares were purchased at an average price of $6.00 per share, with a total value of $9,724,998.00. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link.

Shares of Minerva Neurosciences (NASDAQ:NERV) traded down 0.67% during mid-day trading on Wednesday, hitting $5.93. 43,059 shares of the company’s stock traded hands. Minerva Neurosciences has a one year low of $5.75 and a one year high of $6.38. The stock has a 50-day moving average of $5.99 and a 200-day moving average of $5.99. The company’s market cap is $108.4 million.

Minerva Neurosciences, Inc is a biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (NASDAQ:NERV), diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.